Next Article in Journal
A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer
Previous Article in Journal
Activity of Gallium Meso- and Protoporphyrin IX against Biofilms of Multidrug-Resistant Acinetobacter baumannii Isolates
Open AccessReview

Non-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic Pericarditis

Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, 1110 N. Stonewall Avenue, CPB 214, Oklahoma City, OK 73117, USA
Department of Cardiology, College of Medicine, University of Oklahoma, 825 N.E. 10th Street, 2E, Oklahoma City, OK 74104, USA
Author to whom correspondence should be addressed.
Academic Editor: Jane McHowat
Pharmaceuticals 2016, 9(2), 17;
Received: 13 November 2015 / Revised: 15 March 2016 / Accepted: 16 March 2016 / Published: 23 March 2016
Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) are a mainstay of therapy for the treatment of idiopathic pericarditis (IP). A comprehensive review consisting of pertinent clinical literature, pharmacokinetic, and pharmacodynamic considerations, has not been released in recent years. This review will facilitate the clinician’s understanding of pharmacotherapeutic considerations for using ASA/NSAIDs to treat IP. Data were compiled using clinical literature consisting of case reports, cohort data, retrospective and prospective studies, and manufacturer package inserts. ASA, ibuprofen, indometacin, and ketorolac relatively have the most evidence in the treatment of IP, provide symptomatic relief of IP, and should be tapered accordingly. ASA is the drug of choice in patients with coronary artery disease (CAD), heart failure (HF), or renal disease, but should be avoided in patients with asthma and nasal polyps, who are naïve to ASA therapy. Ibuprofen is an inexpensive and relatively accessible option in patients who do not have concomitant CAD, HF, or renal disease. Indometacin is not available over-the-counter in the USA, and has a relatively higher incidence of central nervous system (CNS) adverse effects. Ketorolac is an intravenous option; however, clinicians must be mindful of the maximum dose that can be administered. While ASA/NSAIDs do not ameliorate the disease process of IP, they are part of first-line therapy (along with colchicine), for preventing recurrence of IP. ASA/NSAID choice should be dictated by comorbid conditions, tolerability, and adverse effects. Additionally, the clinician should be mindful of considerations such as tapering, high-sensitivity CRP monitoring, bleeding risk, and contraindications to ASA/NSAID therapy. View Full-Text
Keywords: idiopathic; pericarditis; non-steroidal anti-inflammatory drugs (NSAIDs); aspirin (ASA) idiopathic; pericarditis; non-steroidal anti-inflammatory drugs (NSAIDs); aspirin (ASA)
MDPI and ACS Style

Schwier, N.; Tran, N. Non-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic Pericarditis. Pharmaceuticals 2016, 9, 17.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop